OBJECTIVE: Oral treatment with oleoyl-estrone induces the loss of body fat and improvement of insulin resistance. Since cholesterol levels are deeply affected by oleoyl-estrone, we investigated here whether short-term treatment affected cholesterol turnover and overall metabolite changes. DESIGN: Wistar female rats received a single oral dose of 10 mmol/kg oleoyl-estrone in 0.2 ml of sunflower oil. Groups of animals were killed at timed intervals and blood samples were taken. In a second experiment series, rats had implanted carotid and jugular cannulas and were given a single gavage of oleoyl-estrone. These rats were used for the measurement of the cholesterol turnover rate. MEASUREMENTS: Body weight change and food intake: Glucose, total and HDL-cholesterol, triacylglycerols, 3-hydroxybutyrate, nonesterified fatty acids, insulin, HOMA score in the rats of the first series. Cholesterol: Cholesterol pool changes and cholesterol turnover rates in the rats of the second series. RESULTS: OE induced early effects, decreasing food intake, cholesterol and HDL-cholesterol levels, and increasing insulin sensitivity (HOMA score). OE also increased cholesteryl-ester turnover, and decreased circulating total cholesterol, especially esterified cholesterol pools. CONCLUSIONS: The role of early changes in insulin sensitivity induced by oral OE cannot explain per se the deep changes in cholesterol handling, essentially a consequence of accelerated lipoprotein turnover. However, the increase in cholesteryl-ester turnover observed with OE treatment may be, at least in part, a consequence of the decrease in insulin resistance. The compounded effect of increased insulin sensitivity and accelerated lipoprotein turnover may help explain the early and marked hypocholesterolaemic effects of OE.
Introduction
Oleoyl-estrone is a powerful hormonal signal inducing the loss of body fat when given in pharmacological doses to rodents. 1 Oral gavages result in a dose-dependent loss of weight, 2 mostly due to the mobilisation of body lipids. This active utilisation of lipid reserves is carried out essentially by decreasing the lipid stores in white adipose tissue, 1 and the increased muscle utilisation of lipids 3 that result in a marked decrease of the respiratory quotient, 1 sparing body protein in a context in which food intake was decreased and energy expenditure maintained. 4 Chronic oleoyl-estrone treatment also induces a decrease in insulin levels and insulin resistance, with maintenance of plasma glucose and liver glycogen. 5, 6 The imbalance between maintained energy expenditure and decreased energy intake induced by oleoyl-estrone treatment is maintained at the expense of lipid stores; 2 the massive mobilisation of adipose tissue lipid, and its oxidation, 1,7 spares glucose and protein, 4 increasing the transport of lipids by the blood. The effects of oleoyl-estrone on plasma lipids have been studied in rats typically after 10-day treatments. Nevertheless, the effects of oleoyl-estrone on food intake were already observable after 2 h of the oral administration of the hormone. 8 Oleoyl-estrone decreases circulating cholesterol, especially in the HDL fraction, 3 but does not alter the body cholesterol pool to a significant extent; 7 thus, any changes in plasma cholesterol dynamics may reflect modifications in lipoprotein turnover in addition to eventual changes in the rates of synthesis or excretion of cholesterol. Since the mobilisation of cholesterol and its transport via the blood is one of the most marked effects of oleoyl-estrone on lipid metabolism, we studied the turnover rate of cholesterol in rat plasma shortly after a single dose of oral oleoyl-estrone, when massive lipid mobilisation had not yet been fully established.
Experimental
Female Wistar rats (from Harlan-Interfauna, Sant Feliu de Codines, Spain) weighing 225-250 g were used. The animals were kept under standard environmental conditions; they were fed maintenance rat chow (Panlab, Barcelona, Spain), containing 13.3 kJ/g metabolisable energy (73% derived from carbohydrate, 19% from protein and 8% from lipid).
The experimental setup and procedures were accepted by the Ethics Committee of the University of Barcelona. All animal handling procedures were carried out following the guidelines established by the EU, and the Spanish and Catalan Governments.
The rats were subjected to a daily oral gavage of 10 mmol/kg and day of oleoyl-estrone (OED, Barcelona, Spain) in 0.2 ml of sunflower oil, by means of a stomach cannula. Controls received only the oil. Two sets of experiments were carried out. In the first, after receiving the first gavage, groups of rats were killed, at 0, 3, 6, 24 and 48 h, by decapitation; their blood was received into dry heparinised beakers. Plasma was extracted and stored at À801C until processed. The blood was later used for the measurement of total cholesterol (Cholesterol reagent easy, Menarini, Firenze Italy), HDL-cholesterol using the same kit after using the HDL-cholesterol precipitant rat reagent (Randox, Antrim, UK), glucose (Trinder kit, Sigma, St Louis, MO, USA), nonesterified fatty acids (Wako Chemicals, Neuss, Germany), 3-hydroxybutyrate (kit 907979, Roche, Mannheim, Germany), total triacylglycerols (kit 11528, Biosystems, Barcelona, Spain) and insulin (SRI-13K kit, Linco, St Charles, MO, USA). The HOMA score 9, 10 was calculated from the insulin and glucose data for each rat.
For the second experiment, in order to prepare cholesterol label-loaded plasma, two untreated intact 'donor' rats were killed and exsaguinated. The plasma was incubated for 18 h with 1.3 kBq/ml (ie 1 nmol) 3 H-labelled cholesterol (TRK330, Amersham Biosciences, Chalfont St Giles, UK) at room temperature 11 in order to equilibrate the label distribution within the different cholesterol pools of the plasma sample. A group of rats were anaesthetized with i.p. sodium pentobarbital (50 mg/kg); two cannulae were then inserted in the right jugular vein using P10 Intramedic plastic tubing (Becton-Dickinson, Franklin Lakes, NJ, USA) and in the left carotid artery, using P50 tubing. The cannulas were filled with heparinised saline. In order to measure the cholesterol turnover, we followed the procedure outlined by Robins et al:
12 a group of cannulated rats received the oral oleoylestrone gavage in oil (or oil alone in the case of controls) and 6 h later, they received 0.20 ml of donor rat plasma (ie 830 kBq of cholesterol label, with a specific activity of 2.26 kBq/nmol for free cholesterol and 530 Bq/nmol for esterified cholesterol), infused through the jugular vein cannula, followed by a bolus of 0.1 ml of saline to clean the cannula. After 2 min, a 0.400 ml sample of blood was drawn from the carotid artery (initial value), and the extractions continued for up to 2 h, when the rats were killed. 12 The experiment was repeated using a second series of cannulated rats injected with 'donor' labelled plasma 3 days after receiving the OE gavage; blood extractions were again extended for up to 2 h. The samples of blood containing labelled cholesterol were centrifuged to obtain plasma, which was extracted with trichloromethane/methanol (2:1 by volume). 13 The lipid extract was used for the estimation of total cholesterol radioactivity, and was subjected to TLC separation of cholesterol and cholesterol fatty esters using silicagel plates (Polygram, Wacherey-Nagel, Düren, Germany), eluted with hexane/ethyl ether/acetic acid (80:20:1 by volume) as mobile phase.
14 Cholesterol esters mean Rf was 0.95 and free cholesterol had an Rf value of 0.26. The areas of free and esterified cholesterol were identified in the plate, cut and counted using a standard liquid scintillation system. Free and esterified cholesterol label data were adjusted to decay curves
where L is the fraction of label remaining in the corresponding plasma pool, P is the initial mass of the cholesterol pool, 8 is a constant (long-term asymptotic value for free cholesterol, zero for cholesterol esters), dt is the time interval studied and K is the decay constant (ie halflife ¼ 1/K).
The approximate sizes of circulating cholesterol pools were estimated from the plasma-unlabelled cholesterol concentrations and the mass of blood in the rat, roughly 5% of body weight, 15 assuming that plasma constitutes about 55% of the blood. Two-way ANOVA and post hoc Bonferroni test were used to establish the differences between groups. Table 1 presents the short-term changes induced by the OE gavage. The 2-day variation in body weight was small but already statistically significant; cumulative food intake was lower in OE-treated rats from the start: in the first 3 h, OEtreated rats ingested only half the food eaten by controls, irrespective of both having received an oil gavage of 7 kJ. In the whole 48 h period, OE-treated rats ingested 32% less food than controls.
Results
Plasma glucose was unchanged by OE treatment, but increased with time. Insulin levels were practically unchanged in controls, but decreased by one-third with respect to controls from 6 h onwards. The HOMA score showed that the sensitivity to insulin tended to increase in controls but was maintained at a low setting in OE-treated animals.
Oleoyl-estrone increases plasma cholesterol turnover C Cabot et al OE-treated rats decreased both total and HDL-cholesterol levels with time. In controls, the HDL/total cholesterol ratio was in the 64-70% range during the whole experiment, but in OE-treated rats decreased steadily, down to 61% at 3 h and to a minimum of 24% after 2 days (15% at 72 h). Thus, the decrease in circulating cholesterol affected more deeply HDL-cholesterol than free cholesterol.
Other lipid metabolism parameters in plasma showed little short-term change with OE treatment. No differences were found due to treatment or time in nonesterified fatty acids and triacylglycerols. The levels of 3-hydroxybutyrate showed a barely significant early increase in OEtreated rats that was later normalised. The data on label decay corresponding to the second experiment are presented in Figure 1 . Free cholesterol label decreased rapidly to very low levels of radioactivity in the first half hour after injection. However, the label in the esterified cholesterol fraction decreased much more slowly. The data obtained 6 h after the gavage were quite similar, both for free and esterified cholesterol, to those obtained after 3 days of treatment. OE accelerated the decay of esterified cholesterol label both at 6 and 72 h of the first OE gavage. Table 2 shows the calculated half-life values for each series of data. The adjustment of data to the decay curves resulted in all cases in r values higher than 0.95. OE decreased the half-life values for esterified cholesterol with no changes in free cholesterol; controls also showed a significant effect of 'time' decreasing (to a lower extent, nevertheless, than under OE treatment) the half-life values of cholesterol esters with the duration of the gavages.
No changes were observed in the free cholesterol plasma pool. However, in OE-treated rats, the HDL-cholesterol pool decreased to 51% (in the 6 h period), and 19% (after 72 h) of the initial HDL cholesterol pool.
Discussion
The present study shows that OE induces early metabolic changes in addition to its well-known mid-and long-term effects on body energy homeostasis. No relevant changes in fatty acid, triacylglycerol or ketone bodies levels were observed in the period studied; however, the deep modifications in cholesterol levels, pool size and turnover suggest a fast enhancement of lipoprotein-dependent interorgan cholesterol transport and metabolism. Data are the mean7s.e.m. of data from six animals per group. Statistical comparison between groups was determined using a two-way ANOVA program. Statistically significant P-values are presented in bold type. *Po0.05 vs controls (Bonferroni post hoc test).
Oleoyl-estrone increases plasma cholesterol turnover C Cabot et al
The insulin sensitivity increased significantly as indicated by the HOMA scores. This modulation of insulin sensitivity, which resulted in maintained glycaemia and decreased insulinaemia, was thus an early effect attributable to oral OE treatment. It is well known that OE decreases insulin resistance, 5, 6 but no short-term effects on this parameter were described previously. The rapid turnover of plasma-free cholesterol showed no differences between controls and OE-treated rats; nevertheless, when these data were taken together with the Oleoyl-estrone increases plasma cholesterol turnover C Cabot et al acceleration of the disposal of esterified cholesterol under OE treatment, the trend to increase the mobilisation of plasma cholesterol by OE became significant, and was dependent on the duration of treatment. The main effect of oleoyl-estrone on plasma cholesterol, thus, can be traced to the increased turnover and shrinking pool of esterified cholesterol, another indication of accelerated lipoprotein handling parallel to white adipose tissue wasting and active lipid oxidation. 4, 7 Insulin resistance alters the handling of lipoproteins, and thus that of HDL-cholesterol. 16, 17 Hyperinsulinaemia also increases the synthesis and decreases the absorption of cholesterol. 18 However, the changes in cholesterol levels are often more directly associated to the consequences of insulin resistance and hyperinsulinaemia 19 than, to small extent, changes in insulin sensitivity such as those observed here. In addition, most effects of insulin resistance on cholesterol levels are mediated by the handling of lipoproteins, such as chylomicra remnants 20, 21 or modulation of lipoprotein lipase. 16, 22 The lack of changes in circulating triacylglycerol may point towards a limited extent of change in lipoprotein lipase, but OE is known to induce marked decreases in adipose tissue and increases in muscle lipoprotein lipase 3 that facilitate the transfer of lipid energy from adipose tissue to peripheral tissues. This means that the steady state of plasma triacylglycerol and nonesterified fatty acids is maintained, but lipoprotein handling is accelerated by OE treatment. 3 The data presented here agree with this interpretation.
The role of early changes in insulin sensitivity induced by oral OE cannot explain per se the deep changes in cholesterol handling, essentially a consequence of accelerated lipoprotein turnover. However, the progressively faster cholesterylester turnover observed with time may be, at least in part, a consequence of the decrease in insulin resistance, since insulin controls this process. 23 This process may be in some way restrained by the marked decrease in hepatic lipase elicited by OE, 3 which may effectively limit the disposal of cholesterol by the liver. The compounded effect of increased insulin sensitivity and increased lipoprotein-lipid turnover may help explain the early and marked hypocholesterolaemic effects of OE.
